Gertrude Stein
If Ms. Stein were a physician, she might proclaim that "a blood vessel is a blood vessel is a blood vessel is a blood vessel" regardless of what organ it supplies. The implication is that blockage of one leads to blockage of others. Thus peripheral artery disease is considered a coronary heart disease equivalent by the Adult Treatment Panel III. For that matter, so is symptomatic carotid artery disease. Most recently, twice in January, studies were published in Circulation: CQ&O and PLoS Medicine linking erectile dysfunction to future heart disease.
Along those lines, we're now familiar with the use of coronary artery calcification scoring to provide additional information for risk stratification beyond the Framingham risk score. While we're struggling to come to grips with primary prevention of heart disease, it's interesting to note that a population-based study published early online last week in Stroke concluded that CAC was useful in predicting future stroke. 4,180 low-intermediate risk participants avg 59yo were followed for ~8 years in order to arrive at this conclusion. Interestingly, 3 other well known studies failed to demonstrate this association, possibly due to a smaller number of participants.
Should we be surprised at this finding? Probably not. In fact, I would go so far as to say that aside from statistics, I was more surprised by the other 3 studies' inability to demonstrate this link. Bottom line, we need to aggressively heart disease risk factors which are remarkably similar to those for stroke.
Tweet
This site complies with the HONcode standard for trustworthy health information:
verify here.
Along this vein (pun intended) of heart disease that Dr. Lin is discussing, we would like to direct readers to this new review in Annals of Long-Term Care in which Dr. William Smucker reviews the new anticoagulants and considerations for safe prescribing in older adults. The new oral anticoagulants dabigatran, rivaroxaban, and apixaban vie to replace warfarin as the gold standard for antithrombotic stroke prophylaxis for patients with atrial fibrillation. Although these agents tout better safety profiles, practitioners should remember the importance of conducting risk-benefit assessments. Read the full article here: http://www.annalsoflongtermcare.com/article/antithrombotic-therapy-atrial-fibrillation-update-safety-evidence-based-treatment-decisions-
ReplyDelete